This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Antibiotic Resistance 2013: The Antibiotics Development Pipeline And Strategies To Combat Antibiotic Resistance

DUBLIN, Ireland, April 2, 2013 /PRNewswire/ --

Research and Markets has announced the addition of the "Antibiotic Resistance 2013: The Antibiotics Development Pipeline and Strategies to Combat Antibiotic Resistance" report to their offering.

     (Logo: http://photos.prnewswire.com/prnh/20130307/600769 )

This report gives a comprehensive overview of global antibiotic resistance, the antibiotics pipeline and new strategies to target resistance mechanisms. It identifies 109 antibiotics in the development pipeline, approximately 70% of which are in early development (Preclinical and Phase 1). In contrast, there are just 9 candidates at Phase 3, while there are 31 at Phase 2. These developments are being progressed by 66 companies, of which nine (14%) are major international corporations and 57 (86%) are Small/Medium Sized Enterprises (SMEs).

While antibiotics are effective for the majority of infections, increasing resistance in some pathogens threatens to undermine the few remaining drugs that are still effective against them. This is evident in the case of Klebsiella pneumoniae. Since 2005, there has been a significant decrease of susceptibility to carbapenems in invasive Klebsiella pneumoniae, causing concerns due to the lack of therapeutic options for treating these infections.

Antibiotic resistance is a long-evolved trait in prokaryotes. The extensive capabilities of the resistome, together with the ability of bacteria to establish new mutant variants in response to man-made antibiotics, suggest that antibiotic resistance will remain an ever-present threat. It is therefore not so much a question of whether a pathogen will become resistant to an antibiotic, but when. However, the development of new drugs and targeting mechanisms provide an opportunity to reset the clock on resistance levels in particular pathogens.

In the last decade, the capacity to target pathogens has also been undermined by a lack of innovation, which has seen a 60% fall in the numbers of new approvals and few novel molecules. However, as this report has shown, this trend is changing. Today, there are more than 100 candidate antibiotics in development, of which half are in the clinical pipeline. While there are several promising candidates at Phase 3 which offer hope of new approvals in the coming years, Phase 2 developments are now substantial, suggesting the emergence of a new era in the types of antibiotics and the strategies that will be available to target pathogens in the future. Key Topics Covered: Executive Summary Chapter 1 Introduction

1.1 Antibiotic Resistance 1.2 Resistance Mechanisms 1.3 The Resistome 1.4 Pathogenomics 1.5 Strategies and Targets 1.6 The Cost of Antibiotic Resistance 1.7 Global Surveillance 1.8 This Report Chapter 2 Antibiotic Resistance, Global Trends 2.1 Antibiotic Resistance 2.2 Europe 2.2.1 Carbapenem-resistant Klebsiella pneumoniae and Pseudomonas aeruginosa (2005 to 2010) 2.2.2 Escherichia coli 2.2.3 Streptococcus pneumoniae 2.2.4 Staphylococcus aureus 2.2.5 Enterococcus faecalis 2.2.6 Klebsiella pneumoniae 2.2.7 Pseudomonas aeruginosa 2.3 Other Countries 2.4 China 2.5 USA 2.6 Kuwait 2.7 Discussion Chapter 3 Marketed Antibiotics 3.1 Marketed Antibiotics 3.2 Mechanisms 3.3 Companies 3.4 Sulphonamides 3.5 Beta Lactams (penicillins, cephalosporins, carbapenems, monobactams) 3.6 Aminoglycosides 3.7 Tetracyclines 3.8 Quinolones/Fluoroquinolones 3.9 Macrolides 3.10 Combinations 3.11 Folate antagonists 3.12 Mycobacterials 3.13 Glycopeptides 3.14 Others 3.15 Discussion Chapter 4 Pipeline Antibiotics 4.1 Pipeline Antibiotics 4.2 Companies 4.3 Phase 3 4.4 Phase 2 4.5 Phase 1 4.6 Preclinical 4.7 Discussion Chapter 5 Discussion 5.1 Background 5.2 Mechanisms 5.3 Multiple Activities 5.4 Marketed Antibiotics 5.5 Antibiotics Pipeline 5.6 Circumventing Resistance 5.7 Resistance Mutations 5.8 Virulence 5.9 Conclusions

For more information visit Antibiotic Resistance 2013: The Antibiotics Development Pipeline and Strategies to Combat Antibiotic Resistance

Research and Markets Laura Wood, Senior Manager. press@researchandmarkets.com U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716

Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

SOURCE Research and Markets

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,070.40 +46.34 0.26%
S&P 500 2,114.49 +6.20 0.29%
NASDAQ 5,016.9290 +11.5380 0.23%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs